share_log

We Think HealthEquity's (NASDAQ:HQY) Robust Earnings Are Conservative

We Think HealthEquity's (NASDAQ:HQY) Robust Earnings Are Conservative

我们认为HealthEquity(纳斯达克股票代码:HQY)的强劲收益是保守的
Simply Wall St ·  2023/12/13 07:04

Even though HealthEquity, Inc.'s (NASDAQ:HQY) recent earnings release was robust, the market didn't seem to notice. Investors are probably missing some underlying factors which are encouraging for the future of the company.

尽管 HealthEquity, Inc.s(纳斯达克股票代码:HQY)最近发布的财报表现强劲,市场似乎没有注意到。投资者可能错过了一些对公司未来感到鼓舞的潜在因素。

Check out our latest analysis for HealthEquity

查看我们对HealthEquity的最新分析

earnings-and-revenue-history
NasdaqGS:HQY Earnings and Revenue History December 13th 2023
纳斯达克股票代码:HQY 收益和收入记录 2023 年 12 月 13 日

The Impact Of Unusual Items On Profit

不寻常物品对利润的影响

Importantly, our data indicates that HealthEquity's profit was reduced by US$13m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If HealthEquity doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

重要的是,我们的数据表明,由于不寻常的项目,HealtheQuity的利润在过去一年中减少了1300万美元。尽管由于不寻常的项目而产生的扣除首先令人失望,但有一线希望。当我们分析全球绝大多数上市公司时,我们发现重要的不寻常项目通常不会重演。鉴于这些细列项目被认为是不寻常的,这并不奇怪。如果HealthEquity看到这些不寻常的支出不会重演,那么在其他条件相同的情况下,我们预计其利润将在来年增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让你想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看根据他们的估计描绘未来盈利能力的交互式图表。

Our Take On HealthEquity's Profit Performance

我们对HealthEquity盈利表现的看法

Unusual items (expenses) detracted from HealthEquity's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that HealthEquity's statutory profit actually understates its earnings potential! And one can definitely find a positive in the fact that it made a profit this year, despite losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about HealthEquity as a business, it's important to be aware of any risks it's facing. At Simply Wall St, we found 1 warning sign for HealthEquity and we think they deserve your attention.

去年,不寻常的项目(支出)减损了HealtheQuity的收益,但明年我们可能会看到改善。基于这一观察,我们认为HealthEquity的法定利润实际上可能低估了其盈利潜力!尽管去年亏损,但它今年还是实现了盈利,这一事实肯定会给人留下积极的印象。当然,在分析其收益时,我们才刚刚浮出水面;人们还可以考虑利润率、预测增长和投资回报率等因素。如果您想进一步了解HealtheQuity作为一家企业,请务必意识到其面临的任何风险。在 Simply Wall St,我们发现了 1 个 HealtheQuity 的警告信号,我们认为它们值得你关注。

This note has only looked at a single factor that sheds light on the nature of HealthEquity's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

本说明仅研究了揭示HealtheQuity利润性质的单一因素。但是,还有很多其他方法可以告知你对公司的看法。有些人认为高股本回报率是高质量业务的好兆头。尽管可能需要代表你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发